Eisai india sales. Institutional Sales at Eisai Pharmaceuticals India Pvt Ltd.

Eisai india sales. Company Introduction:EISAI PHARMACEUTICALS INDIA PRIVATE LIMITED is the Indian subsidiary of Eisai Co. 5bn) in the second half of its 2024 fiscal year, down approximately $90m from the original $370m figure. The company operates in India with a strong commitment to its "human health care (hhc)" mission Apr 11, 2018 · The sale agreement is based on collaboration with Biogen Eisai Pharmaceuticals India, a leading Japanese pharmaceutical company in India, has commenced sales of Biogen’s multiple sclerosis (MS) portfolio in India based on a collaboration agreement between Eisai India’s parent company Eisai and Biogen for India and other Asian countries. The company operates in India with a strong commitment to its "human health care (hhc)" mission At Eisai Pharmaceuticals India Pvt. Eisai Sales careers offer excellent training and paths to senior and leadership roles. Shares in the company opened 0. 2006 Acquisition of Four Anticancer Drugs from Ligand Pharmaceuticals, Inc. in),Located in . 8 Eisai India reviews in Mumbai (India). They fully embrace the spirit of human health care. 3 Eisai India reviews. (“the Company”) and its affiliates (collectively referred to as “the Group”) List of Group Companies Company Name Under the agreement, Eisai distributes and books sales for Biogen’s MS treatments, Avonex (interferon beta 1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate)and Plegridy (peginterferon beta-1a) in India. Eisai India is a research-based human health care (hhc) company that discovers, develops and markets Welcome to the Eisai Official Corporate Website Eisai Co. Apr 12, 2018 · Under the agreement, Eisai distributes and books sales for Biogen’s MS treatments, AVONEX (interferon beta 1a), TYSABRI (natalizumab), TECFIDERA (dimethyl fumarate) and PLEGRIDY (peginterferon beta-1a) in India. 5 billion announced in May. · Experience: Eisai Pharmaceuticals India · Education: PUMBA · Location: Pune · 138 connections on LinkedIn. View information on-Eisai pharmaceuticals india (eisai. Are you experienced in specialty sales with a strong background in oncology? Join a dynamic team focused on meeting sales goals by promoting therapeutic products, building relationships with healthcare professionals, and conducting market analysis. -based Ligand Pharmaceuticals, Inc. Overview of Eisai's Initiatives for Dementia Eisai India’s Initiatives for Eliminating Lymphatic Filariasis News Release Latest News Information October 8, 2024 “URECE® TABLETS” (DOTINURAD) APPROVED IN THAILAND FOR GOUT AND HYPERURICEMIA October 4, 2024 Eisai Announces Status and Completion of Acquisition of Own Shares Eisai Pharmaceuticals Headquarters and Office Locations Eisai Pharmaceuticals is headquartered in Visakhapatnam, India, and has 3 office locations. Dec 13, 2023 · Eisai's news release “LEQEMBI® Intravenous Infusion” (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20 is posted. Welcome to the Eisai Official Corporate Website Corporate Information Page. 4 days ago · Welcome to the Eisai Official Corporate Website Eisai Co. Executive · looking for opportunities, 10 Years of Extensive experience as Sales Executive( Health care Executive) with a demonstrated history of working in the pharmaceuticals industry. Solutions-oriented professionals with pharmaceutical sales experience should apply. 548 likes. In total, sales of JPY 1. View Askar Surisetty’s profile on LinkedIn, a professional Eisai Co. View Shumitra Datta’s profile on LinkedIn, a professional community of 1 billion members. Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the company believes could be finally nearing a “growth expansion phase Meet Eisai's leaders who inspire all of us to meet all of our patients' needs. ,Ltd was the first Japanese company to have a 100% subsidiary in Indian pharmaceutical market. In order for us to respond to all customer inquiries as quickly and helpfully as possible, please direct your inquiry to the appropriate office for your country or region. The team works closely with other departments to ensure a motivated and well-supported Eisai was built from an inspired team of innovators relentlessly pursuing way to improve the lives of patients. (“the Company”) and its affiliates (collectively referred to as “the Group”) List of Group Companies (As of March 31, 2023) EIL is Eisai’s subsidiary in India and is responsible for process research, manufacturing and sales of pharmaceutical products. Eisai also expanded considerably in Europe during this period with 4 days ago · Welcome to the Eisai Official Corporate Website Eisai Co. Learn how hhc inspires our products and explore our medicines today. Mar 20, 2025 · Eisai’s ongoing efforts to build an ecosystem platform business, as part of its medium-term business plan EWAY2025, support its adaptability and responsiveness to technological trends. At Eisai caring for people is our work. In the third quarter of Eisai’s 2024 fiscal year—which ran from October to December 2024—Leqembi made Territory Sales Executive at Eisai Pharmaceuticals India · Professional with several years of rich experience in pharmaceutical sales. Strong sales professional with a Master in Pharmaceutical Management, focused in various pharmaceuticals MBA IN MARKETING AND SALES · Experience: Eisai Pharmaceuticals India · Education: MMM Engineering College, Gorakhpur, UP · Location: Delhi · 31 connections on LinkedIn. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd (“Eisai South Africa”), a pharmaceutical sales subsidiary recently established in Johannesburg, South Africa, and direct sales operations and business activities have commenced in Feb 6, 2024 · Stockholm, Sweden, February 6, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2023 (third quarter of Eisai’s fiscal year, ending March 2024). Jan 6, 2023 · Eisai is committed to ensuring that certain financially disadvantaged patients have access to LEQEMBI. 3 million. It is Eisai’s policy to comply with all applicable federal, state and local laws and regulations regarding non-discrimination in employment and not to discriminate against any employee or applicant for employment on the basis of actual or perceived race, color, creed, religion, national origin, ancestry, alienage or citizenship status, age Eisai Co. Eisai Pharmaceuticals India is a Pharmaceutical Manufacturing, Manufacturing General, and Oncology company located in Visakhapatnam, Andhra Pradesh with $5. Upon breaking into the world's top 20 pharmaceutical companies at the start of the 21st century, Eisai's global business made another dramatic leap forward propelled by stellar contributions from sales of Aricept and Pariet (AcipHex in the United States), with its overseas sales ratio in 2002 exceeding 50% for the first time. Regional Sales Manager at Eisai Pharmaceuticals India · Performance-oriented Sales Leader offering exceptional record of achievement over 11 years career. · Location: Ghaziabad · 39 connections on LinkedIn. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has submitted a new drug application for mecobalamin (development code: E0302) as a treatment for amyotrophic lateral sclerosis (ALS) in Japan. Successful 12 years in Healthcare Sales. Throughout my… · Experience: Eisai Pharmaceuticals India · Education: Cornell University · Location: Andhra Pradesh · 500+ connections on LinkedIn. Firstly, Eisai is establishing a Patient Assistance Program, which will provide LEQEMBI at no cost, for eligible uninsured and underinsured patients, including Medicare beneficiaries, who meet financial need and other program criteria. This would 4 days ago · Welcome to the Eisai Official Corporate Website Eisai Co. 1 billion in revenue and 612 employees. 92% higher than the previous market We work tirelessly to discover and develop products that give patients and their families the strength to keep fighting. Mar 26, 2025 · Eisai has lowered its fiscal year 2027 sales projections for its Biogen-partnered Alzheimer’s disease therapy Leqembi, pointing to the drug’s “delayed uptake in the US market. Nov 8, 2024 · Stockholm, Sweden, November 8, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs from April 2024 through March 2025. · Experience: Eisai Pharmaceuticals India Pvt Ltd. Eisai will advance preparations such as technical transfer, process validation, stability test, towards the full scale operations scheduled to start by the end of fiscal Regional Business Manager, Eisai Pharmaceuticals India Pvt Ltd · Pharmaceutical Sales professional with 17years of experience with six different states of India exposure and three different therapies of the industry explored in this tenors. 3%, driven by favorable shifts in product mix. Find over 48 employees information, adress, official website, private emails, phone numbers, revenue, social accounts and nore stuff related to Eisai pharmaceuticals india. View Jayanta Chakraborty’s profile on LinkedIn, a professional community of 1 billion members. Tenacious manager with strategic and analytical approach to solving problems, bringing in customers and accomplishing targets. (Eisai India) was incorporated in October 2004, with registered office at Mumbai. for the acquisition of four oncology-related products. View karan kapoor`’s profile on LinkedIn, a professional community of 1 billion members. The team works closely with other departments to ensure a motivated and well-supported Jul 10, 2025 · Eisai Pharma is set to establish a new Global Capability Center (GCC) in Visakhapatnam, aiming to boost its digital transformation efforts in India. Book a demo today. Conclusion Eisai Pharmaceuticals India Pvt. Jan 14, 2025 · Eisai's news release FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease is posted. Page. " With the desire to empower patient and the people in the daily living domain to “realize their fullest life”, we aim to evolve into an hhceco (hhc concept + ecosystem) company by creating solutions based on science and data in 2 Eisai India reviews. Eisai had overcome the chaotic postwar period and achieved rapid growth through the development of successful products such as its Chocola series, but the company's overall sales were still no more impressive than many newer pharmaceutical firms. Sneh Samir Gupta is a seasoned professional in the pharmaceutical industry, currently serving as Regional Sales Manager at Eisai Pharmaceuticals India since October 2023. Ltd’s (Eisai India) Vizag Plant (Vizag Sales And Marketing Specialist at Eisai Pharmaceuticals India · Experience: Eisai Pharmaceuticals India · Location: Lucknow. May 15, 2024 · Naito waxed poetic as Eisai laid out an ambitious goal to hit 56. View Ramender Guleria’s profile on LinkedIn, a professional community of 1 billion members. Current Openings Health Care Executive Department:Sales CNS 4 days ago · Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. ) For a list of Eisai offices for each country and region along with website links and our Contact Form Jul 10, 2025 · Eisai Pharma is set to establish a new Global Capability Center (GCC) in Visakhapatnam, aiming to boost its digital transformation efforts in India. , we dedicate our work to realize Eisai's corporate concept of hhc (human health care). Find accurate contact data easily with LeadIQ. , Asia, Europe, Russia, India, Africa, the Middle East, Australia and it's Apr 1, 2024 · Eisai's news release Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U. (“the Company”) and its affiliates (collectively referred to as “the Group”) List of Group Companies Company Name Feb 7, 2025 · Eisai’s Biogen-partnered Alzheimer’s therapy Leqembi is “on track” to meet a fiscal year 2024 revenue goal of ¥42. Lanbau Desa Karang Asem Barat, Kecamatan Citeureup, Kabupaten Bogor, 16810 Jawa-Barat, Indonesia. Marketing Executive · Accomplished Pharmaceutical Sales Representative with a strong history of surpassing sales goals and developing lasting relationships with clients. 5 billion yen (roughly $364 million) in global Leqembi sales for the 2024 fiscal year, which will wrap up next March. Strong sales professional with a Master of Business Administration (MBA) focused in Apr 19, 2015 · Japan-based Eisai said it has merged its two India subsidiaries, Eisai Pharmaceuticals India based in Mumbai and Eisai Pharmatechnology and Manufacturing based in Visakhapatnam. May 27, 2015 · Eisai Co. JI. 36 Eisai India reviews. The company operates in India with a strong commitment to its "human health care (hhc)" mission . (Eisai India) was incorporated in March 2007, with Registered office at Visakhapatnam. Zonal Sales Specialist ( Multiple Sclerosis)- North & East India at Eisai Pharmaceuticals India · Working as a Health care Manager in Eisai Pharma. ’s profile on LinkedIn, a professional community of 1 billion members. Sales Representative at Eisai Pharmaceuticals India · Experience: Eisai Pharmaceuticals India · Location: Hyderabad · 4 connections on LinkedIn. Mar 25, 2025 · According to Eisai's simulation, Leqembi sales for fiscal year 2027 are projected to reach 250 to 280 billion Japanese yen ($1. " Specially built sales and distribution software for Pharmaceutical, Healthcare, Life Science, FMCG and food beverages and many more. ALS is an intractable, progressive, neurodegenerative disease that causes severe muscle atrophy and weakness in the muscles. Learn more about Eisai Pharmaceuticals India's company details, contact information, competitors, and more. co. With this agreement, we acquired our first oncology products and began to strengthen our anti-cancer sales structure. (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Explore our locations. sales continuing to drag. Company Introduction: EISAI PHARMACEUTICALS INDIA PRIVATE LIMITED is the Indian subsidiary of Eisai Co. Viatris, Cipla and Aurobindo will make generic versions of GSK's long-acting HIV PrEP med in India. R&D expenses accounted for 20. S. Welcome to Eisai India. With operations in the U. Apr 2015 Implemented MM&SD modules for Eisai India domestic business with a focus on managing sales, inventory and procurement functions of the business. View Nilesh Bhosle’s profile on LinkedIn, a professional community of 1 billion members. At Eisai, our strategists, scientists, researchers, and manufacturers turn inspirations into transformative solutions for patients. Nov 8, 2024 · Eisai has lowered the sales forecast for its Alzheimer’s drug Leqembi (lecanemab), primarily citing delays in revenue in the US. This includes talent acquisition, onboarding, training and development, performance management, employee engagement, and compliance with regulatory employment standards. · Experience: Eisai Pharmaceuticals India Pvt. Oct 30, 2024 · EISAI India. Feb 11, 2016 · Japan's government is looking to procure more generic drugs to help relieve its healthcare budget, and Eisai intends to cash in on that shift by offering its own India-made APIs to competitors. Skilled in Market Analysis, Pharmaceutical & Surgical equipment Sales, Product Launch, Team Management, and Sales Effectiveness. Jun 2, 2020 · Eisai's news release EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO™ (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA is posted. A free inside look at company reviews and salaries posted anonymously by employees. Eisai Co. · Education: Gujarat University · Location: Ahmedabad · 497 connections on LinkedIn. (“the Company”) and its affiliates (collectively referred to as “the Group”) List of Group Companies Company Name At Eisai, we come together around one shared mission: to give our first thoughts to patients and their families and to increase the benefits that health care provides to them. Overview of Eisai's Initiatives for Dementia Eisai India’s Initiatives for Eliminating Lymphatic Filariasis News Release Latest News Information October 8, 2024 “URECE® TABLETS” (DOTINURAD) APPROVED IN THAILAND FOR GOUT AND HYPERURICEMIA October 4, 2024 Eisai Announces Status and Completion of Acquisition of Own Shares Mar 29, 2024 · March 29, 2024 Eisai signed a joint statement with the World Health Organization (WHO) in November 2010 to provide diethylcarbamazine (DEC) tablets, a treatment for lymphatic filariasis (LF), for free of charge. 5 billion (approximately SEK 3 billion) for the period, down from JPY 56. In 2006, Eisai entered into an agreement with U. Eisai (pronounced 'ā-zī’) is derived from the Japanese word for 'health product' and, here at Eisai, we discover, develop and market innovative, high quality medicines Welcome to Eisai India. Ltd. 8 billion). 1 billion were recorded in the period, resulting in a royalty to BioArctic amounting to SEK 7. John's school firozabad · Location: Delhi · 260 connections on LinkedIn. ” In a corporate presentation on Tuesday, Eisai’s sales simulations for Leqembi came out to ¥250 billion to ¥280 Institutional Sales at Eisai Pharmaceuticals India · Experience: Eisai Pharmaceuticals India · Location: Delhi. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices. Explore Eisai Medical's comprehensive oncology resources, including medical information, disease resources, and research updates tailored for healthcare professionals (HCPs). The Japanese pharma expects its lead product co-developed with Biogen to generate $280m (Y42. Mar 30, 2023 · Eisai and Biogen are poised to realize $12. · Education: Post Graduate Degree College, Dharamshala, H. 9 billion in revenue from Alzheimer's drug Leqembi through 2028, according to GlobalData Healthcare. Regional Manager at Eisai Pharmaceuticals India Private Limited. It carries out research and manufacturing of new active pharmaceutical ingredients (API) and formulations. Learn more about us and our mission today. Learn more about our solutions today. Feb 1, 2024 · For Print （276KB） February 1, 2024 Eisai Co. Eisai Group has expanded the main figures of its contribution from the current "patients and their families" to "patients and the people in the daily living domain. View Joseph Kiran Kumar’s profile on LinkedIn, a professional community of 1 billion members. , a leading global research-based pharmaceutical company headquartered in Japan. Total Experience is 8 years in CNS · Experience: Eisai Pharmaceuticals India · Education: St. Focused on sales orientation, people development Jun 2, 2025 · Japanese company Eisai announced on May 29, 2025 that it has received a favorable judgment in United States District Court in New Jersey against India-based manufacturer Shilpa Medicare (1). · Experienced Regional Manager with a demonstrated history of working in the hospital & health care industry. Nov 20, 2024 · EISAI COMMENCES FULLY-FLEDGED BUSINESS ACTIVITIES AT PHARMA SALES SUBSIDIARY IN SOUTH AFRICA COMMENCEMENT OF DIRECT SALES OPERATIONS IN AFRICA, AND ESTABLISHMENT OF BRANCH OFFICE IN KENYA January 26, 2024 EISAI SUBMITS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRAHIGH-DOSE FORMULATION IN JAPAN FOR THE INDICATION OF AMYOTROPHIC LATERAL SCLEROSIS Eisai Pharmaceuticals India employs 607 employees. May 15, 2025 · Eisai expects Leqembi sales to rise 73% in fiscal year 2025 to JPY76. , based in Tokyo, Japan. Aug 29, 2025 · We are dedicated to transforming drug discovery by developing targeted treatments for challenging neurological conditions and driving innovations toward a cancer-free future. In addition to the QA departments at Eisai manufacturing sites in Japan, the United States, the UK, China, India and Indonesia, Eisai has established a structure that can rapidly respond to events which happen in each region and country, assigning Quality Assurance Managers at each Eisai marketing affiliate to deal with complaint handling Eisai Pharmaceuticals India - Top Contacts of Directors, Heads, CEO & Top Employees Below Table Displays all the recently available contact numbers of top decision makers of Eisai Pharmaceuticals India including HR, Marketing, Sales, Finance, CEO and other directors & other employees contact numbers. Get insights into the Eisai Oncology Global Medical Affairs by accessing the latest information on tumor types, tumor microenvironment and various types of cancer treatment. Under the agreement, Eisai distributes and books sales for Biogen’s MS treatments,AVONEX® (interferon beta 1a), TYSABRI® (natalizumab), TECFIDERA® (dimethyl fumarate)and PLEGRIDY® (peginterferon beta-1a) in India. Eisai Farmacêutica, Unipessoal Lda. Access Eisai Pharmaceuticals India's email format and Eisai Pharmaceuticals India staff directory for direct contact details of 505 employees. Eisai is one of the world's leading research-based pharmaceutical companies. A Leading Global Research and Development-Based Pharmaceutical Company Headquartered in Japan Established in 1941, Eisai is a pharmaceutical company operating globally in terms of R&D, manufacturing and marketing, with a strong focus on prescription medicines. The Eisai Pharmaceuticals India management team includes Hemant Nikam (Sr Director and Head Human Resources), Vishnu Sharma (Training Manager), and Urvashi Soni (Deputy Manager Legal). 5bn ($525. The company operates in India with a strong commitment to its "human health care (hhc)" mission Thank you for your interest in Eisai. The environmental protection costs of our group companies in Japan, calculated with reference to the "Environmental Accounting Guidelines 2005" issued by the Ministry of the Environment, are as follows: Apr 12, 2018 · Under the agreement, Eisai distributes and books sales for Biogen’s MS treatments, AVONEX (interferon beta 1a), TYSABRI (natalizumab), TECFIDERA (dimethyl fumarate) and PLEGRIDY (peginterferon beta-1a) in India. (EIL) was incorporated in March 2007. View Sanjay K Pathak’s profile on LinkedIn, a professional community of 1 billion members. According to a press release announcing the court’s decision, Shilpa had submitted an Abbreviated New Drug Application (ANDA) to FDA for a generic version of lenvatinib mesylate, which Eisai markets as Area Sales Manager at Eisai Pharmaceuticals India · Experience: Eisai Pharmaceuticals India · Location: 221001. After product development, production and distribution of high-quality DEC tablets commenced in 2013 at Eisai Pharmaceuticals India Pvt. FDA is posted. View dalveer S. These trends and challenges will influence the sales trajectory and competitive landscape for Eisai’s top-selling drugs in the coming years. Salaries posted anonymously by Eisai employees. The company operates in India with a strong commitment to its "human health care (hhc)" mission Institutional Sales at Eisai Pharmaceuticals India Pvt Ltd. Adept in providing crucial information regarding newly launched and established pharmaceutical products to clients. I bring a wealth of experience in IT to drive successful business outcomes. Company Type: Primarily a pharmaceutical manufacturer, also engaged in sales, marketing, and distribution. 9 billion in sales through 2028. (“the Company”) and its affiliates (collectively referred to as “the Group”) List of Group Companies (As of March 31, 2023) Sales Support-MIS Coordinator- Sales Administrator at Eisai Pharmaceuticals India Pvt. Sep 25, 2023 · Eisai's news release “LEQEMBI® Intravenous Infusion” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan is posted. Get the latest business insights from Dun & Bradstreet. At Eisai Pharmaceuticals India Pvt. Since there is only one medicine Sales And Marketing Specialist at Eisai Pharmaceuticals India · Experience: Eisai Pharmaceuticals India · Location: 700014 · 1 connection on LinkedIn. eisai · Experience: Eisai Pharmaceuticals India · Location: New Delhi · 181 connections on LinkedIn. Eisai Pharmaceuticals India Pvt. Specialized in Ophthalmology and Oncology. View Bantaram Venkat’s profile on LinkedIn, a professional community of 1 billion members. Welcome to the Eisai Official Corporate Website Eisai: The First 80 Years Page. GlobalData expects Eisai and Biogen's Leqembi to accumulate $12. Prior experience includes the role of Business Manager at Merck from April 2022 to October 2023, and Senior Therapy Manager at MSD from September 2011 to April 2022. View MITESH BHATIA’s profile on LinkedIn, a professional Jan 30, 2025 · Welcome to the Eisai Official Corporate Website Initiatives Toward Eliminating Lymphatic Filariasis (LF)-Steady Advancement in the Implementation of Mass Drug Administration and LF elimination with the Efforts and Dedication of Eisai India- Page. Jun 19, 2025 · Welcome to the Eisai Official Corporate Website Latest News Page. The company operates in India with a strong commitment to its "human health care (hhc)" mission Sep 4, 2025 · Welcome to the Eisai Official Corporate Website Eisai's News Release Page. (Headquarters: Tokyo, President and CEO: Hauro Naito) today announced the completion of construction of the Eisai Knowledge Centre, India, the Company’s new manufacturing and process research base in India. · Experience: Eisai Pharmaceuticals India · Education: University of Mumbai · Location: Mumbai · 201 connections on LinkedIn. Sales Executive at Eisai Pharmaceuticals India · Experience: Eisai Pharmaceuticals India · Location: Ganderbal · 8 connections on LinkedIn. Apr 11, 2018 · Under the agreement, Eisai distributes and books sales for Biogen’s MS treatments,AVONEX ® (interferon beta 1a), TYSABRI ® (natalizumab), TECFIDERA ® (dimethyl fumarate)and PLEGRIDY ® (peginterferon beta-1a) in India. A free inside look at Eisai salary trends based on 634 salaries wages for 339 jobs at Eisai. Eisai India product portfolio includes prescription medicines in several therapeutic areas such as central nervous Dec 17, 2009 · Eisai Co. View Pervaiz Ahmad’s profile on LinkedIn, a professional community of 1 billion members. The Human Resources team at Eisai Pharmaceuticals India is responsible for managing all aspects of employee relations and development. View Jagdish Patil’s profile on LinkedIn, a professional Careers Let us work together to create a better world. Skilled in Microsoft Excel, Management, Customer Service, Strategic Planning, and Sales Management. This estimate is based upon 2 Eisai India Regional Sales Manager salary report (s) provided by employees or estimated based upon statistical methods. Sales Manager - North India at Eisai Pharmaceuticals India Pvt. Jan 9, 2024 · Eisai's news release “LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China is posted. Eisai now expects Leqembi sales to total JPY 42. It has some 10,000 employees, among them about 1,500 in research. A proven track record and strategic planning skills are essential for success in this fast-paced environment. Read about their impact here. Regional Sales Manager salaries at Eisai India can range from ₹9,72,802-₹12,06,364. , Ltd. Sep 17, 2025 · Welcome to the Eisai Official Corporate Website Eisai Co. Ability to effectively generate leads for pharmaceutical products, market them, and increase business Feb 8, 2025 · Gross profit increased 9% to 473 billion yen, while the cost-to-sales ratio improved to 21. 6 billion to $1. Remarkable Impact on patients lives. EIL conducts API (active pharmaceutical ingredient) process research as well as manufacturing of API and oral solid dose products at the “Eisai Knowledge Center India,” located in southern India at Visakhapatnam (Vizag), Andhra Pradesh, and has a sales office Welcome to Eisai India. How much do Eisai India employees make? Glassdoor provides our best prediction for total pay in today's job market, along with other types of pay like cash bonuses, stock bonuses, profit sharing, sales commissions, and tips. Explore Eisai Pharmaceuticals India's employee directory to find accurate email addresses and contact information. Satisfying unmet medical needs and increasing benefits to patients, their families, and caregivers is Eisai’s human health care (hhc) mission. It Health Care Executive at Eisai Pharmaceutical private limited · Experienced Therapy Business Manager with a demonstrated history of working in the hospital & health care industry. View Soumen Roy’s profile on LinkedIn, a professional community of 1 billion members. 1m) as the Alzheimer's biologic progresses in the US and Japan from pathway establishment and demand stimulation into the demand expansion phase of its launch. At Eisai Pharmaceuticals India Pvt. Eisai (pronounced 'ā-zī’) is derived from the Japanese word for 'health product' and, here at Eisai, we discover, develop and market innovative, high quality medicines throughout the world. · 8+ Year Experience in FMCG & Nutrition sector as a Sales Support coordinator & Sales MIS executive. We are committed to increasing benefits to patients and the people in the daily living domain. The company operates in India with a strong commitment to its "human health care (hhc)" mission Welcome to Eisai Pharmaceuticals India Pvt. It covers basic information of Company Eisai Pharmaceuticals India Pvt Ltd including business area, product portfolio, buying portfolio, subsidiary, manufacturing location, certifications, competition peer, financials, patent filed, warning letter, pipeline products, recent news, detailed analysis encompassing technical, commercial, supplier Find company research, competitor information, contact details & financial data for EISAI PHARMACEUTICALS INDIA PRIVATE LIMITED of Mumbai, Maharashtra. The number of MS patients has increased in India in recent years. · Experience: Eisai Pharmaceuticals India · Education: Andhra University · Location: Visakhapatnam · 292 connections on LinkedIn. 5 billion ($279 million)—despite U. P. All of Eisai's breakthrough medicines are developed around our human health care mission. 8% of revenue, reflecting Company Type: Primarily a pharmaceutical manufacturer, also engaged in sales, marketing, and distribution. Eisai Pharmaceuticals India is a Pharmaceuticals company located in Plot # 96,97,98,124 & 126, RamkyPharma City (SEZ), Parawada, Visakhapatnam, Andhra Pradesh 531019, IN with 505 employees. · Best of services and brands in Neonatology to customer. It is a subsidiary of global Japanese pharmaceutical company, Eisai Co. [3] Feb 5, 2012 · Eisai Knowledge Centre is located in the Special Economic Zone at the Jawaharlal Nehru Pharma City in Visakhapatnam, Andhra Pradesh, India. (For global-related issues, please contact our global head office in Tokyo, Japan. Aug 5, 2025 · Welcome to the Eisai Official Corporate Website Latest Major R&D Pipeline Page. Skilled in Sales, Communication, Management, Medical Sales, and Networking. View ROHIT YADAV’s profile on LinkedIn, a professional community of 34 Eisai India reviews. Seven years of team handling in southern and eastern part of the country leading various teams. vjcpgf hyc7i jfj buuu eoe dmiqsm omc edc geef atfqu4